SMTI

SEC Filing Summary: Wound Management Technologies, Inc. (10-Q)

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2011, for Wound Management Technologies, Inc. (WMT), a smaller reporting company focused on advanced wound care products, primarily the patented CellerateRX line. The company markets activated collagen products for diabetic wound applications and is developing orthopedic bone void fillers. Operations are funded primarily through debt and equity issuances rather than sustainable operating cash flow.

Key Financial Metrics

Note: Total debt includes current and long-term notes payable and debentures net of discounts. Significant non-cash expenses related to debt origination and conversion inflated the net loss.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 543% year-over-year (YoY) for the six-month period, driven by a $500,000 upfront non-refundable payment from a new exclusive distribution agreement with Juventas, LLC for North American rights to CellerateRX powder.
• Expense Surge: General and Administrative (G&A) expenses rose 85% YoY, and interest expense increased 257% YoY. A significant portion of the net loss is attributed to $3.04 million in debt-related expenses (loan origination fees and amortization of discounts) and a $1.38 million loss on debt settlement.
• Balance Sheet Shift: Total assets increased from $6.78 million to $9.28 million, largely due to an increase in Notes Receivable from related parties ($2.35 million) and cash inflows from financing activities. However, the company maintains a working capital deficit (Current Liabilities of $3.39M vs. Current Assets of $3.08M).

Outlook, Risks, and Contingencies

• Going Concern: Management explicitly states that the company has current liabilities in excess of current assets and has not developed a reliable source of revenue to fund existence. These conditions raise substantial doubt about the company's ability to continue as a going concern.
• Debt Structure: The company relies heavily on convertible notes with beneficial conversion features (BCF) and warrants, resulting in high non-cash interest expenses. As of the filing date, $371,111 of a specific note balance was in default.
• Tax Liabilities: The company is delinquent on federal payroll taxes from 2004-2005. Unpaid taxes total approximately $123,577, with penalties and interest of $214,319. A tax lien was filed in December 2009, and settlement negotiations are ongoing.
• Royalty Obligations: The company owes $75,502 in accrued royalties to Applied Nutritionals, LLC, following a $375,000 payment made in March 2011 to meet minimum annual royalty requirements.
• Management Commentary: Management expects revenues to exceed the cost of doing business in the second half of 2011, contingent on the success of the Juventas distribution agreement and international expansion.

Investor Verification Checklist

• Debt Default Status: Verify the current status of the $371,111 note balance reported as in default and any subsequent acceleration of debt.
• IRS Settlement: Confirm the outcome of negotiations regarding the 2004-2005 payroll tax lien and the total final settlement amount.
• Related Party Transactions: Scrutinize the $2.35 million in notes receivable from related parties (including entities controlled by the CEO) and the terms of the $346,650 in notes payable to related parties.
• Revenue Sustainability: Assess whether the $500,000 upfront payment from Juventas is a recurring revenue stream or a one-time event, and verify progress on the $9 million minimum sales target for 2012.
• Liquidity Runway: Evaluate the sufficiency of the $206,335 cash balance against the high monthly burn rate driven by debt service and operating expenses.